司库奇尤单抗可能触发强直性脊柱炎或银屑病关节炎患者炎症性肠病
该研究基于英国10家医院2016至2019年起始司库奇尤单抗治疗的306例AS和PsA患者,评估治疗期间胃肠道相关不良事件(GIRAE)及既存IBD情况。结果显示新发IBD绝对率低,但既存IBD且为AS的患者GIRAE风险明显更高,应考虑替代治疗。
要点
- 306例患者中24例(7.8%)出现GIRAE,明确IBD仅4例(1.3%)。
- 明确IBD病例均为AS患者并停药,其中2例为既存IBD,2例为新发。
- 既存IBD的7例中5例出现GIRAE,提示该类患者风险更高。
核心结论
- 起始司库奇尤单抗患者新发IBD绝对率低,多数GIRAE患者无客观IBD证据且未停药。
- 既存IBD且为AS的患者GIRAE风险明显更高,处方时应考虑替代方案。
研究设计与样本
- 回顾性多中心队列研究,纳入英国10家医院2016至2019年起始司库奇尤单抗的AS或PsA患者306例。
- GIRAE分为明确(活检证实IBD、明确时间关联、停药后症状缓解、无更可能替代解释)、很可能(符合明确但无活检证实)或可能(胃肠道症状未达明确或很可能标准)。
主要发现
- 306例中124例(40.5%)为AS,182例(59.5%)为PsA。
- 24例(7.8%)起始司库奇尤单抗后出现GIRAE,其中明确IBD 4例(1.3%)、很可能IBD 7例(2.3%)、可能IBD 13例(4.2%)。
- 明确IBD病例均为AS患者并停用司库奇尤单抗,其中2例为既存IBD,2例(0.7%)为新发,新发病例中1例需手术干预。
- 7例(2.3%)起始前已诊断IBD,其中5例出现GIRAE。
临床怎么用
- 对既存IBD的AS患者,处方司库奇尤单抗前应评估GIRAE风险并考虑替代治疗。
- 治疗期间出现胃肠道症状时,多数患者无客观IBD证据,需结合活检等客观检查判断。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Real-world secukinumab gastrointestinal-related adverse events (GIRAE) data during treatment for AS and PsA are lacking. We aimed to obtain this through baseline evaluation of pre-existing IBD rates and predictors of GIRAE. METHODS: Patient electronic and paper records commencing secukinumab from 10 UK hospitals between 2016 and 2019 were reviewed. GIRAE after initiation were defined as: definite [objective evidence of IBD (biopsy proven), clear temporal association, resolution of symptoms on drug withdrawal, no alternative explanation felt more likely], probable (as per definite, but without biopsy confirmation) or possible (gastrointestinal symptoms not fulfilling definite or probable criteria). RESULTS: Data for all 306 patients started on secukinumab were analysed: 124 (40.5%) AS and 182 (59.5%) PsA. Twenty-four of 306 (7.8%) experienced GIRAE after starting secukinumab. Amongst patients who developed GIRAE, four (1.3%) had definite, seven (2.3%) probable and 13 (4.2%) possible IBD. All definite cases were patients with AS and stopped secukinumab; two had pre-existing IBD and two (0.7%) were de novo cases of which one required surgical intervention. Seven patients (2.3%) had pre-existing diagnoses of IBD prior to initiation, of which five patients experienced GIRAE. CONCLUSION: Absolute rates of new IBD in patients starting secukinumab are low. The majority of patients developing new GIRAE did not develop objective evidence of IBD or stop therapy. For patients with pre-existing IBD and AS the risk of GIRAE is much higher, and prescribing alternatives should be considered.
引用
- Onac IA, Clarke BD, Tacu C, et al. Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients. Rheumatology (Oxford). 2021. PMID: 33677579. doi:10.1093/rheumatology/keab193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。